Innoviva (INVA) Assets Average (2011 - 2026)
Innoviva (INVA) reported Assets Average of $1.7 billion for Q1 2026, up 35.86% on a YoY basis from $1.3 billion in Q1 2025, and up 13.3% quarter-over-quarter from $1.5 billion in Q4 2025.
Innoviva (INVA) Assets Average (2011 - 2026) Analysis & Trends
Innoviva has reported Assets Average for 16 years, with the latest figure at $1.7 billion in Q1 2026.
- For the quarter ending Q1 2026, Assets Average rose 35.86% year-over-year to $1.7 billion; the trailing twelve-month figure through Mar 2026 stood at $1.7 billion (up 35.86% YoY), and the FY2025 full-year result was $1.5 billion, up 20.99% from the prior year.
- Assets Average for Q1 2026 stood at $1.7 billion, up from $1.5 billion in the prior quarter.
- The five-year high for Assets Average was $1.7 billion in Q1 2026, with the low at $1.0 billion in Q1 2022.
- Historically, Assets Average has averaged $1.3 billion across 5 years, with a median of $1.2 billion in 2024.
- Annual changes were most pronounced in 2022 — Assets Average surged 47.06% — and 2023, when it retreated 6.45%.
- Innoviva's Assets Average stood at $1.3 billion in 2022, then retreated by 4.99% to $1.2 billion in 2023, then climbed by 4.16% to $1.3 billion in 2024, then climbed by 20.99% to $1.5 billion in 2025, then gained by 13.3% to $1.7 billion in 2026.
- The last three Assets Average figures came in at $1.7 billion (Q1 2026), $1.5 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 33.42 Mn |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | 795.91 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 13.04 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 1.72 Bn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 40.89 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | 26.03 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 10.06 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 26.06 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 660.38 Mn |
| 10 | Innoviva | 1.69 Bn | 1.08 Bn | 75.83 Mn | 1.74 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.74 Bn |
| Dec 31, 2025 | 1.53 Bn |
| Sep 30, 2025 | 1.38 Bn |
| Jun 30, 2025 | 1.29 Bn |
| Mar 31, 2025 | 1.28 Bn |
| Dec 31, 2024 | 1.27 Bn |
| Sep 30, 2024 | 1.23 Bn |
| Jun 30, 2024 | 1.25 Bn |
| Mar 31, 2024 | 1.26 Bn |
| Dec 31, 2023 | 1.22 Bn |
| Sep 30, 2023 | 1.15 Bn |
| Jun 30, 2023 | 1.12 Bn |
| Mar 31, 2023 | 1.18 Bn |
| Dec 31, 2022 | 1.28 Bn |
| Sep 30, 2022 | 1.23 Bn |
| Jun 30, 2022 | 1.12 Bn |
| Mar 31, 2022 | 1.02 Bn |
| Dec 31, 2021 | 906.82 Mn |
| Sep 30, 2021 | 838.19 Mn |
| Jun 30, 2021 | 938.72 Mn |